알테오젠의 파트너사 MSD(북미 내 Merck)는 키트루다(Keytruda)와 키트루다 큐렉스(Keytruda Qlex)가 Padcev과 병용으로 근침윤성 방광…
Merck.com
FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patien…
If approved, these would be the first and only immunotherapy plus antibody-drug conjugate perioperative treatment regimens for patients with MIBC regardless of cisplatin eligibility Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug …
